Synergistic Combination of N-Acetylcysteine and Ribavirin to Protect from Lethal Influenza Viral Infection in a Mouse Model

Oxidative stress is implicated in the pathogenesis of pulmonary damage during viral infections. In a previous study we observed a significant improvement of survival of influenza-infected mice with NAC, 1g/kg divided in two daily administrations, for 8 days including a pretreatment on day 1 before i...

Full description

Saved in:
Bibliographic Details
Published in:International journal of immunopathology and pharmacology 2004-01, Vol.17 (1), p.99-102
Main Authors: Ghezzi, P., Ungheri, D.
Format: Article
Language:English
Subjects:
Acetylcysteine - therapeutic use
Animals
Disease Models, Animal
Drug Synergism
Influenza A virus - drug effects
Influenza A virus - immunology
Influenza virus
Male
Mice
Orthomyxoviridae Infections - drug therapy
Orthomyxoviridae Infections - mortality
Orthomyxoviridae Infections - prevention & control
Ribavirin - therapeutic use
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oxidative stress is implicated in the pathogenesis of pulmonary damage during viral infections. In a previous study we observed a significant improvement of survival of influenza-infected mice with NAC, 1g/kg divided in two daily administrations, for 8 days including a pretreatment on day 1 before infection. In order to test NAC in a more realistic model, we studied the effect of combined treatment with NAC and the antiviral drug, ribavirin. Since in the present work we wanted to test a possible synergistic effect by combination of NAC and ribavirin, we used a different NAC's treatment regimen (1 g/kg, once a day for 4 days) that, alone, did not significantly protect mice from death. Mice (12 per group) infected intranasally with a lethal dose of influenza A virus APR/8. NAC was given as a single daily dose of 1000 mg/kg starting from 4 h after infection and until day 4 after infection, in association with ribavirin (100 mg/kg, ip). End-point evaluation was 14-day survival. With this schedule survival in infected mice was 17%, it was not significantly changed by NAC (25%). Survival increased to 58% with ribavirin and to 92% (n=12) with a combined treatment with ribavirin and NAC. This suggest that antioxidant therapy can increase survival by either improving the defenses against virus or by protecting from the pathogenesis of lung inflammation.
ISSN:0394-6320
2058-7384
DOI:10.1177/039463200401700114